2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2114

Interstitial Pneumonia with Autoimmune Features (IPAF): Are There Definable Subsets?
Abstract Number: 2115

Mast Cell Activation Features in Ehlers-Danlos/Joint Hypermobility Patients: A Retrospective Analysis in Light of an Emerging Disease Cluster
Abstract Number: 2116

Evaluation of Connective Tissue Diseases in Patients Presenting with Interstitial Lung Disease in a Referral Center in Santiago, Chile
Abstract Number: 2117

C-Reactive Protein and Serum Amyloid a in Sepsis, Acute Appendicitis and Familial Mediterranean Fever
Abstract Number: 2118

Asymptomatic Tendinitis of Flexor Digitorum Tendons in Patients with Type 2 Diabetes : A Single-Center, Cross-Sectional Prevalence Study
Abstract Number: 2119

Rheumatological Immune Related Adverse Events in Malignancy Patients Treated with Anti-Programmed Cell Death (PD) 1 Antibodies
Abstract Number: 2120

Quality, Content and Readability Assessment of Patient Education Websites Relating to Ehlers-Danlos Syndrome
Abstract Number: 2121

Autoantibodies As Biomarkers for the Identification of Pre-Clinical Stages of Autoimmune Diseases: Demonstration of Inflammatory and Fibrotic Activity in the Liver of Asymptomatic and Biochemically Normal Individuals with Anti-Mitochondria Antibodies
Abstract Number: 2122

Association of Retroperitoneal Fibrosis with Malignancy
Abstract Number: 2123

Protein-Losing Enteropathy in Patients with Systemic Autoimmune Diseases: Characterization of 263 Cases (GEAS-SEMI Spanish Cohort)
Abstract Number: 2124

Mixed Connective Tissue Disorder Has Higher Prevalence of Arthritis and Use of Methotrexate Than Systemic Lupus Erythematosus
Abstract Number: 2125

Identification of Long-Term Prognostic Factors for Relapse or Exacerbation in Patients with Pulmonary Sarcoidosis: A Single Center Long-Term Observational Cohort Study
Abstract Number: 2126

Safety of Immune Checkpoint Inhibitors for the Treatment of Melanoma, Bronchopulmonary and Urologic Neoplasms in Patients with Preexisting Autoimmune Disease
Abstract Number: 2127

Tumor Necrosis Factor Inhibitors for Sarcoidosis
Abstract Number: 2128

A Systematic Review of the Management of Patients with Preexisting Rheumatologic Diseases Receiving Checkpoint Inhibitors for Cancer

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].